Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge: Physician Experiences with REMS Programs (CDER)
Data To Support Social and Behavioral Research as Used by the Food and Drug Administration
Physician Survey - Ambrisentan
Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge: Physician Experiences with REMS Programs (CDER)
OMB: 0910-0847
⚠️ Notice: This form may be outdated. More recent filings and information on OMB 0910-0847 can be found here: